Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14347785 | 0.77 | ALDH1A1 (0.41) | ALDH1A1MAPTHTTPTK2 | |
| SCHEMBL21160937 | 0.71 | GAA (0.40) | ALDH1A1 | |
| SCHEMBL21719731 | 0.65 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL6762227 | 0.64 | ALDH1A1 (0.50) | ALDH1A1MAPT | |
| SCHEMBL21719457 | 0.60 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL22876742 | 0.60 | ALDH1A1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL20734527 | 0.60 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL22911355 | 0.60 | — | — | |
| SCHEMBL21211958 | 0.60 | — | — | |
| SCHEMBL22125849 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | Terns, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | ALDH1A1 1027/4885CYP3A4 4049/4885CYP2D6 3994/4885 |
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | ABL1, ABL2, BCR | ALDH1A1 497/4885CYP3A4 1098/4885CYP2D6 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.